Author

S. J. Miner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. M. Chinnaiyan· 4 shared A. Parolia· 4 shared R. Mannan· 4 shared X. Cao· 4 shared E. Young· 3 shared F. Su· 3 shared J. C.-Y. Tien· 3 shared L. Xiao· 3 shared

Activity by Year

2024-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. M. Chinnaiyan

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer

J. Luo, Z. Chen, Y. Qiao, J. C.-Y. Tien, E. Young, R. Mannan, S. Mahapatra, T. He, S. Eyunni, Y. Zhang, Y. Zheng, F. Su, X. Cao, R. Wang, Y. Cheng, , A. M. Chinnaiyan

This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.

bioRxiv · Mar 29, 2024Cancer Biology

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

J. C.-Y. Tien, Y. Chang, Y. Zhang, J. Chou, Y. Cheng, X. Wang, J. Yang, R. Mannan, P. Shah, X.-M. Wang, A. J. Todd, S. Eyunni, C. Cheng, R. J. Rebernick, L. Xiao, , A. M. Chinnaiyan

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

bioRxiv · Mar 20, 2024Cancer Biology

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

T. He, C. Cheng, Y. Qiao, H. Cho, E. Young, R. Mannan, S. Mahapatra, S. J. Miner, Y. Zheng, N. Kim, V. Z. Zeng, J. P. Wisniewski, S. Hou, B. Jackson, X. Cao, , A. M. Chinnaiyan

This paper develops an orally bioavailable PROTAC degrader of mSWI/SNF ATPases for prostate cancer and identifies resistance mechanisms through long-term treatment.

bioRxiv · Feb 29, 2024Cancer Biology

Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies

T. He, L. Xiao, Y. Qiao, O. Klingbeil, E. Young, X. S. Wu, R. Mannan, S. Mahapatra, S. Eyunni, J. C.-Y. Tien, X. Wang, Y. Zheng, N. Kim, H. Zheng, S. Hou, , A. M. Chinnaiyan

This study identifies a therapeutic vulnerability in POU2F-POU2AF-driven cancers by showing that targeting the mSWI/SNF complex with a PROTAC degrader reduces tumor growth in preclinical models.

bioRxiv · Jan 22, 2024Cancer Biology